Predictmedix AI Executives Departing This Weekend for Strategic Collaborations in India
Predictmedix AI Executives Departing This Weekend for Strategic Collaborations in India
TORONTO, ON / ACCESSWIRE / September 20, 2023 / Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) (the "Company" or "Predictmedix") today announced that visas have been granted for a strategic visit to India. The primary purpose of the company's executives' visit is to engage with institutional partners and government officials in India, with a keen focus on ensuring seamless integration and scalable deployment of Predictmedix's cutting-edge contactless AI solutions. This strategic move underscores the company's commitment to revolutionizing healthcare and enhancing various industry sectors through the power of AI.
多倫多,2023年9月20日/ACCESSWIRE亞洲網加利福尼亞州聖約瑟10月23日電Predidicmedix AI Inc.(CSE:PMED)(場外市場代碼:PMEDF)(FRA:3QP)(以下簡稱“公司”或“PredidicMedix”)今天宣佈,已為對印度進行戰略訪問發放了簽證。該公司高管此行的主要目的是與印度的機構合作夥伴和政府官員接觸,重點確保Predidicmedix的尖端非接觸式人工智慧解決方案的無縫集成和可擴展部署。這一戰略舉措突顯了該公司致力於通過人工智慧的力量來變革醫療保健並增強各行業的實力。
India, with its dynamic and rapidly evolving market, offers a unique opportunity for Predictmedix AI to make a significant impact. By collaborating with local partners and government authorities, we aim to usher in a future where AI-driven technologies enhance efficiency, safety, and the overall well-being of the nation.
印度,憑藉其充滿活力和快速發展的市場,為Predidicmedix AI提供了一個獨特的機會來產生重大影響。通過與當地合作夥伴和政府當局合作,我們的目標是迎來人工智慧驅動技術提高效率、安全和國家整體福祉的未來。
"Our visit to India holds immense importance for us, as we look forward to collaborating with institutional partners and government officials to bring our transformative AI solutions to a wider audience. By ensuring seamless integration and scalable deployment, we aim to make a significant positive impact on healthcare and various other sectors in India. We believe that this collaboration will pave the way for a future where AI-driven technologies enhance efficiency, safety, and the overall well-being of the nation," commented Dr. Rahul Kushwah, COO of Predictmedix AI.
PredidicMedix AI首席運營官Rahul Kushwah博士評論道:“我們的印度之行對我們來說非常重要,因為我們期待著與機構合作夥伴和政府官員合作,將我們變革性的人工智慧解決方案帶給更廣泛的受眾。通過確保無縫集成和可擴展的部署,我們的目標是對印度的醫療保健和其他各個部門產生重大的積極影響。我們相信,這種合作將為人工智慧驅動的技術提高效率、安全性和國家整體福祉的未來鋪平道路,”PredicicMedix AI的首席運營官Rahul Kushwah博士評論道。
About Predictmedix AI Inc.
關於PredicicMedix AI Inc.
Predictmedix AI Inc. (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn.
PredicicMedix AI Inc.(CSE:PMED)(OTCQB:PMEDF)(FRA:3QP)是一家新興的全球快速健康篩查和遠端患者護理解決方案提供商。該公司的安全入口站由專有人工智慧(AI)提供支持,使用多光譜相機分析生理數據模式並預測各種健康問題,包括傳染病(如新冠肺炎)、藥物或酒精損害、疲勞或各種精神疾病。PredicicMedix AI的專有遠端患者護理平臺使醫療專業人員能夠使用一套人工智慧支持的工具來改善患者的健康結果。要了解更多資訊,請訪問我們的網站,或在Twitter、Instagram或LinkedIn上關注我們。
Public Relations Contact
公共關係聯繫人
For further media information or to set up an interview, please contact:
欲瞭解更多媒體資訊或安排採訪,請聯繫:
Nelson Hudes
Communications International (905) 660 9155
Nelson@hudescommunications.com
納爾遜·胡德斯
國際通信(905)660 9155
郵箱:nelson@hudesCommunication ations.com
Dr. Rahul Kushwah (647) 889 6916
拉胡爾·庫什瓦博士電話:(647)889 6916
Caution Regarding Forward-Looking Information:
有關前瞻性資訊的警告:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.
本新聞稿可能包含基於當前預期的前瞻性陳述和資訊。這些聲明不應被解讀為對公司未來業績或結果的保證。這類陳述涉及已知和未知的風險、不確定因素和其他因素,可能導致實際結果、業績或成就與這類陳述所暗示的大不相同。雖然這些陳述是基於管理層的合理假設,但不能保證這些假設將被證明是正確的。我們不承擔更新或修改它們以反映新事件或新情況的責任。本公司的證券尚未根據修訂後的《1933年美國證券法》(下稱《美國證券法》)或適用的州證券法進行註冊,除非進行註冊或獲得適用的豁免,否則不得向美國境內的人或美國人提供或出售,或為美國境內的人或“美國人”的賬戶或為他們的利益服務。本新聞稿不應構成出售要約或徵求購買要約,也不應在美國或任何司法管轄區出售任何此類要約、徵求或出售將是非法的證券。此外,存在已知和未知的風險因素,可能導致公司的實際結果、業績或成就與本文包含的前瞻性資訊明示或暗示的未來結果、業績或成就的第4頁存在實質性差異,這些風險因素包括但不限於對獲得監管部門批准的依賴;獲得與其技術相關的知識產權的能力;有限的經營歷史;一般的商業、經濟、競爭、政治、監管和社會不確定性,尤其是與新冠肺炎相關的不確定性;與公司無法控制的因素相關的風險,包括與新冠肺炎相關的風險;與公司股票相關的風險,包括可能或可能不在該方控制範圍內的事件導致的價格波動;對管理層的依賴;以及行業中更多競爭對手的緊急情況。
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
本文中的所有前瞻性資訊都受本警示聲明的約束,公司沒有義務修改或更新任何此類前瞻性資訊,也沒有義務公開宣佈對本文中包含的任何前瞻性資訊的任何修改結果,以反映未來的結果、事件或發展,除非法律要求。
Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
免責聲明:“本公司目前不會明示或默示聲稱其產品有能力診斷、消除、治癒或控制新冠肺炎(或SARS-2冠狀病毒)。
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
加拿大證券交易所尚未對本新聞稿的充分性或準確性進行審查,也不承擔任何責任。
SOURCE: Predictmedix AI Inc.
資料來源:Predicate Medix AI Inc.